Filters








378,027 Hits in 3.7 sec

Retrospective Analysis of Chemoradiotherapy for Limited-Stage Small-Cell Lung Cancer

Jong Hoon Lee, Sung Hwan Kim, Su Zy Kim, Joo Hwan Lee, Hoon Kyo Kim, Byoung Yong Shim
2009 The Journal of the Korean Society for Therapeutic Radiology and Oncology  
The 2-year progression-free survival rate was 16.0 percent for the sequential arm and 50.0 percent for the concurrent arm (p=0.0950 by log-rank test).  ...  Results: The median progression-free survival time was 16.5 months (95% confidence interval [CI], 9.0 to 24.1 months) for the sequential arm, and 26.3 months (95% CI, 16.6 to 35.9 months) for the concurrent  ...  Progression-free survival (PFS) was measured from the date of histologic or cytologic confirmation to the date of the first observation of disease progression or death.  ... 
doi:10.3857/jkstro.2009.27.3.133 fatcat:dw36lq5hd5cqrazyjuib5d25mq

CISPLATIN AND ETOPOSIDE WITH EITHER CONCURRENT OR SEQUENTIAL RADIATION THERAPY IN LIMITED-STAGE SMALL CELL LUNG CANCER

Niveen Abo-Touk
2009 Research in Oncology  
Progression-free and overall survivals tended to be higher in the concurrent arm than those in the sequential arm (P =0.09 and 0.07, respectively).  ...  Conclusion: Concurrent use of cisplatin and etoposide with radiation therapy in limited-stage small cell lung cancer is preferred than sequential treatment.  ...  No response was defined as stabilization or <50% reduction in measurable disease. Progression was defined as an increase of >25% of at least one lesion or the appearance of a new malignant lesion.  ... 
doi:10.21608/resoncol.2009.407 fatcat:4usi2csc6fcobn7h6d33rlsany

Concurrent Hyperfractionated Radiotherapy and Low-Dose Daily Carboplatin and Paclitaxel in Patients With Stage III Non–Small-Cell Lung Cancer: Long-Term Results of a Phase II Study

Branislav Jeremic, Biljana Milicic, Ljubisa Acimovic, Slobodan Milisavljevic
2005 Journal of Clinical Oncology  
Concurrent radiochemotherapy for patients tage Ill non-small cell lung cancer (NSCLC Long-term re Oncol Biol Phy 20.  ...  Progression of disease was defined as an increase of greater than 25% in the sum of the products of the cross-sectional diameters of measured lesions, together with an increase in assessable disease or  ... 
doi:10.1200/jco.2005.07.015 pmid:15718310 fatcat:e2odzl3rkrfgnhstftfvqe2uli

Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial†

M. Reck, I. Bondarenko, A. Luft, P. Serwatowski, F. Barlesi, R. Chacko, M. Sebastian, H. Lu, J. -M. Cuillerot, T. J. Lynch
2012 Annals of Oncology  
This phase 2 study evaluated ipilimumab + paclitaxel (Taxol)/carboplatin in extensive-disease-small-cell lung cancer (ED-SCLC).  ...  End points included progression-free survival (PFS), irPFS, best overall response rate (BORR); irBORR, overall survival (OS), and safety.  ...  Per irRC, new lesions, whether measurable or not, were not considered progression.  ... 
doi:10.1093/annonc/mds213 pmid:22858559 fatcat:a4oryoykajd63gxbhbptp25n4q

Irinotecan and Cisplatin Combination Chemotherapy Plus Concurrent Thoracic Irradiation for Patients with Limited Disease Small Cell Lung Cancer

Junshik Hong, Yae Min Park, Seok Ho Lee, Kyu Chan Lee, Se Hoon Park, Jinny Park, Sun Jin Sym, Eun Kyung Cho, Dong Bok Shin, Jae Hoon Lee
2011 Journal of Lung Cancer  
Purpose: To evaluate the antitumor activity and safety of irinotecan plus cisplatin combination chemotherapy with concurrent thoracic radiotherapy (TRT) in patients with limited disease (LD) small cell  ...  Materials and Methods: Patients with pathologically-confirmed LD SCLC with the following inclusion criteria were retrospectively analyzed: age ≥18 years; measurable lesion; Eastern Cooperative Oncology  ...  We additionally measured time to progression (TTP), in which the deaths of patients from other than progression were censored compared to PFS.  ... 
doi:10.6058/jlc.2011.10.1.49 fatcat:fydhx65cund45od4fc4prnvzne

Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data

Audrey Mauguen, Jean-Pierre Pignon, Sarah Burdett, Caroline Domerg, David Fisher, Rebecca Paulus, Samithra J Mandrekar, Chandra P Belani, Frances A Shepherd, Tim Eisen, Herbert Pang, Laurence Collette (+9 others)
2013 The Lancet Oncology  
Two meta-analyses were of adjuvant chemotherapy in non-small-cell lung cancer, three were of sequential or concurrent chemotherapy, and one was of modifi ed radiotherapy in locally advanced lung cancer  ...  Although reliable and simple to measure, this endpoint takes years to observe. Surrogate endpoints that would enable earlier assessments of treatment eff ects would be useful.  ...  (B) Treatment eff ects on progression-free survival eff ects for radiotherapy plus concurrent chemotherapy compared with radiotherapy alone in non-small-cell lung cancer.  ... 
doi:10.1016/s1470-2045(13)70158-x pmid:23680111 pmcid:PMC3732017 fatcat:wxdd3rus2ravllcsz2esjfjji4

Nintedanib—A case of treating concurrent idiopathic pulmonary fibrosis and non‐small cell lung cancer

Shakti Dabholkar, Bo Gao, Brian Chuong
2022 Respirology Case Reports  
Nintedanib with chemotherapy has shown improvements in survival in non-small cell lung cancer (NSCLC).  ...  Remarkably, progress imaging at 2 years showed further regression of her lung adenocarcinoma, with stability of IPF.  ...  Progress CT imaging showed improving pulmonary fibrosis but, interestingly, there was further progressive reduction in the size of the lung cancer, measuring 7 Â 4 mm in July 2021 (Figure 2B ).  ... 
doi:10.1002/rcr2.902 pmid:35059200 pmcid:PMC8756078 fatcat:adglflowhzae7js4ndezzaevgm

The Association Between Clinical and Radiographic Periodontitis Measurements During Periodontal Maintenance

Jeffrey B. Payne, Pirkka V. Nummikoski, David M. Thompson, Lorne M. Golub, Julie A. Stoner
2013 Journal of Periodontology  
The odds of ABH loss were higher among sites with concurrent oneyear ABD loss versus no change (OR=3.15, p<0.0001) or concurrent PD increases versus no change (OR=1.88, p=0.0025) when considering one-and  ...  Relative clinical attachment level (RCAL) and probing depth (PD) measures were made.  ...  This periodontal stability resulted in a relatively small number of sites that demonstrated disease progression or improvement.  ... 
doi:10.1902/jop.2012.120484 pmid:23205917 pmcid:PMC3612134 fatcat:o7cpcz27ljclvb7gmjznscy7zy

FVC variability in patients with IPF and role of 6-min walk test to predict further change

Steven D. Nathan, Ming Yang, Elizabeth A. Morgenthien, John L. Stauffer
2020 European Respiratory Journal  
Considering additional clinical variables in trial endpoints may provide the ability to identify small changes in FVC that represent disease progression.  ...  can more accurately predict disease progression than short-term changes in FVC alone.  ...  As demonstrated by our analysis, additional measures of disease progression could validate small declines in FVC as clinically meaningful and, thus, enrich the number of patients with IPF who meet a clinical  ... 
doi:10.1183/13993003.02151-2019 pmid:32029447 pmcid:PMC7236864 fatcat:swuunbgmbvelxiqsisfjja43vu

Pretreatment SUV max Value for Predicting Outcome in Stage III NSCLC Patients Receiving Concurrent Chemoradiotherapy

Gokhan Yaprak
2019 İstanbul Kuzey Klinikleri  
In this subgroup, which is difficult to manage, studies that address the role of PET-CT to predict outcome measures specifically for stage III NSCLC receiving concurrent chemoradiotherapy may help better  ...  high risk of progression and death.  ...  Progression-free survival (PFS) was defined as the time between the beginning of concurrent chemoradiotherapy and the date of disease progression or death, whichever comes first.  ... 
doi:10.14744/nci.2019.02212 pmid:31297478 pmcid:PMC6593921 fatcat:w6cmnw5axvdzbmu3ygj2pn7xuy

Second primary cancer in survivors following concurrent chemoradiation for locally advanced non-small-cell lung cancer

N Takigawa, K Kiura, Y Segawa, Y Watanabe, H Kamei, T Moritaka, T Shibayama, H Ueoka, K Gemba, T Yonei, M Tabata, T Shinkai (+5 others)
2006 British Journal of Cancer  
We report outcomes of 92 patients who underwent chemoradiation for unresectable stage III non-small-cell lung cancer, with a median followup of 8.9 years.  ...  Despite the small sample size in these studies, a significant number of patients treated with concurrent CRT for locally advanced unresectable stage IIIA and IIIB NSCLC survived more than 5 years.  ...  The most common site of initial failure was within the site of original disease (local progression only, n ¼ 28; local plus distant progression, n ¼ 8; distant progression only n ¼ 24; unspecified, n ¼  ... 
doi:10.1038/sj.bjc.6603422 pmid:17031394 pmcid:PMC2360581 fatcat:s6x5xp3vmjckhpqitm2jq3twja

Investigating Optimal Progress Measures for Verification of the WebSocket Protocol

Lars Michael Kristensen
2014 Norsk Informatikkonferanse  
The sweepline method has been applied to many concurrent systems, but the optimality of progress measures in terms of the peak number of states stored has not been investigated.  ...  The method relies on a progress measure capturing inherent progress in the system under verification to store only fragments of the state space in memory at a time and thereby reduce peak memory usage.  ...  The lower bounds can be efficiently computed using Tarjan's algorithm for small configurations of a system under verification and used to experimentally assess the optimality of a progress measure.  ... 
dblp:conf/nik/Kristensen14 fatcat:ljzp4fmuxzf4npe47n4x7h7eyy

A Phase II Study of Concurrent Chemoradiation with Weekly Docetaxel, Carboplatin, and Radiation Therapy Followed by Consolidation Chemotherapy with Docetaxel and Carboplatin for Locally Advanced Inoperable Non-small Cell Lung Cancer (NSCLC)

Anshu K. Jain, Randall S. Hughes, Alan B. Sandler, Afshin Dowlati, Lee S. Schwartzberg, Tracy Dobbs, Larry Schlabach, Jean Wu, Nancy J. Muldowney, Hak Choy
2009 Journal of Thoracic Oncology  
The current standard of care for good performance status patients with locally advanced non-small cell lung carcinoma is concurrent chemoradiation, although a clearly superior regimen has not been identified  ...  Progression free survival at 1 year was 27%. Median survival time was 12 months. Median time to progression was 8 months. The primary hematologic toxicity was leukopenia.  ...  All patients had measurable or assessable disease.  ... 
doi:10.1097/jto.0b013e3181a5275c pmid:19404213 fatcat:vvwhyk3u25cddg7foepfsx6hvq

Page 414 of Journal of Clinical Oncology Vol. 12, Issue 2 [page]

1994 Journal of Clinical Oncology  
Patient Evaluation Only a small minority of patients had measurable disease, so regression rate was not used as a study end point.  ...  Progression was declared if the nonmeasurable patient developed measurable areas of malignant disease, if there was an increase in existent measurable areas of malignant disease (> 25%), if there was a  ... 

Accelerated hyperfractionation field-involved re-irradiation combined with concurrent capecitabine chemotherapy for locally recurrent and irresectable rectal cancer

D-S Sun, J-D Zhang, L Li, Y Dai, J-M Yu, Z-Y Shao
2012 British Journal of Radiology  
Small bowel obstruction was severely late toxicity, and the incidence was 1.4%.  ...  The overall median survival time and median progressionfree survival time were 32 and 17 months, respectively. 3 year overall survival and progression-free survival were 45.12% and 31.19%, respectively  ...  Overall survival (OS) was calculated from the LRIRC concurrent chemoradiation date until the last follow-up or death, and progression-free survival (PFS) was calculated from the first day of treatment  ... 
doi:10.1259/bjr/28173562 pmid:21385917 pmcid:PMC3473987 fatcat:kkoouwu4h5evjopxdlcohbzfmi
« Previous Showing results 1 — 15 out of 378,027 results